Mizuho analyst Ann Hynes raised the firm’s price target on Encompass Health to $82 from $77 and keeps a Buy rating on the shares. The analyst increased estimates post the Q4 report. Given the strong fundamentals in the inpatient rehabilitation business, continued improvement in labor trends, bed expansion strategy and acquisition, the visibility is strong for Encompass, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on EHC:
- Encompass Health Highlights Adjusted Financial Metrics
- Encompass Health reports results for fourth quarter 2023 and issues 2024 guidance
- Encompass Health sees FY24 adjusted EPS $3.77-$4.06, consensus $3.84
- Encompass Health reports Q4 adjusted EPS 95c, consensus 82c
- Encompass Health assumed with an Outperform at William Blair